Christopher Marai
Stock Analyst at Nomura
(2.43)
# 2,487
Out of 4,976 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $9.81 | +9,685.93% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $56.19 | -41.27% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $5.13 | +1,654.39% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $455.03 | -83.74% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $4.26 | +275.59% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $141.35 | +177.33% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.94 | +1,652.58% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $17.60 | +1,206.82% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $16.33 | -26.52% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $8.49 | +123.79% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $2.74 | +1,469.34% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $9.81
Upside: +9,685.93%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $56.19
Upside: -41.27%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $5.13
Upside: +1,654.39%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $455.03
Upside: -83.74%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $4.26
Upside: +275.59%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $141.35
Upside: +177.33%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.94
Upside: +1,652.58%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $17.60
Upside: +1,206.82%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $16.33
Upside: -26.52%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $8.49
Upside: +123.79%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $2.74
Upside: +1,469.34%